You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
| Title |
Serious stomatitis and esophagitis: a peculiar mucous reaction induced by pegylated liposomal doxorubicin*
|
|---|---|
| Published in |
Anais Brasileiros de Dermatologia, January 2015
|
| DOI | 10.1590/abd1806-4841.20153708 |
| Pubmed ID | |
| Authors |
Han Ma, Meilan Chen, Junru Liu, Ying Li, Juan Li |
| Abstract |
Pegylated liposomal doxorubicin is an important antineoplastic agent with activity in a variety of solid tumors. It has a totally different profile of pharmacokinetics and toxicity compared with doxorubicin. It rarely causes side-effects like cardiotoxicity or hair loss, but frequently results in many kinds of mucocutaneous reactions, including palmar-plantar erythrodysesthesia, diffuse follicular rash, intertrigo-like eruption, new formation of melanotic macules, stomatitis and radiation recall dermatitis. We present a rare case of multiple myeloma who immediately developed serious stomatitis and esophatitis associated with minor palmar-plantar erythrodysesthesia after a single course of pegylated liposomal doxorubicin. |
Mendeley readers
The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 22 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 3 | 14% |
| Student > Master | 3 | 14% |
| Student > Doctoral Student | 2 | 9% |
| Other | 2 | 9% |
| Student > Ph. D. Student | 2 | 9% |
| Other | 3 | 14% |
| Unknown | 7 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 32% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 9% |
| Nursing and Health Professions | 1 | 5% |
| Environmental Science | 1 | 5% |
| Economics, Econometrics and Finance | 1 | 5% |
| Other | 3 | 14% |
| Unknown | 7 | 32% |